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Introduction
Triple-negative breast cancer (TNBC) has the worst prognosis among all subtypes of breast cancer (BC) featuring genomic instability due to abnormal DNA repair systems caused by mutations in BRCA1/2 and/or other genes involved in homologous recombination (HR) repair mechanism [1] . Therefore, DNAdamaging compounds such as platinum have been widely explored and showed promising efficacy in the treatment of TNBC [1] . CBCSG006 trial is by far to our knowledge the largest randomized, multicenter phase III clinical trial investigating the efficacy of cisplatin combination therapy in metastatic TNBC (mTNBC), which showed that cisplatin plus gemcitabine (GP) treatment significantly prolonged progression-free survival (PFS) compared with paclitaxel plus gemcitabine (GT) treatment [2] . To improve efficacy of platinum-based therapy and avoid substantial toxicity in some patients, biomarkers of better benefit of platinum were widely explored.
TNT trial, TBCRC009 trial and PrECOG0105 trial suggested that the platinum had better performance in patients with germline BRCA1/2 (gBRCA1/2) mutations, while results about homologous recombination deficient (HRD) classification as a biomarker for platinum yielded different results [3] [4] [5] . However, data of GeparSixto trial showed that patients with wild-type BRCA1/2 had better carboplatin effect [6] . TBCRC009 and PrECOG0105 are single-arm studies with limited efficacy in identifying the biomarkers. TNT trial and GeparSixto trial are by far to our knowledge the only two randomized trials with control arms that are more appropriate for assessment of biomarkers. However, both TNT trial and GeparSixto trial focused on carboplatin but not cisplatin, and their results were inconsistent with each other, and only TNT trial focus on metastatic setting. Therefore, whether gBRCA1/2 mutations and HR panel classification could serve as biomarkers of cisplatin-based chemotherapy in metastatic setting needs further investigation.
PD-L1 expression has been shown to correlate with efficacy of chemotherapy and prognosis in BC. In GeparSixto cohort, PD-L1 mRNA expression was significantly linked to increased pathologic complete response (pCR) rate in TNBC, but it could not provide predictive information of pCR rates between patients treated with and without carboplatin [7] . Few study included patients with mTNBC and no large clinical trial has explored the predictive value of PD-L1 expression in cisplatin-based chemotherapy. Therefore, our exploration of the predictive value of PD-L1 expression using CBCSG006 cohort is urgently necessary.
We reported the up-to-date survival data of CBCSG006 trial, and prospectively investigated potential biomarkers for cisplatinbased first-line chemotherapy for TNBC using the updated survival data. In addition, we investigated the absolute survival benefits between two arms in CBCSG006 trial in order to build a model for patient selection procedure.
Methods

Study designs
The design and conduct of CBCSG006 trial was reported previously and is summarized in the supplementary material, available at Annals of Oncology online [2] . Briefly, Between 14 January 2011 to 14 November 2013, 236 eligible women with previously untreated, histologically confirmed metastatic TNBC were randomly assign (1 : 1) to GP or GT arm. About 132 and 114 patients agreed to provide blood and tissue samples, respectively, which were collected before treatment for investigation of potential biomarkers (supplementary Figure S1 , available at Annals of Oncology online).
Pathologic assessment and gene mutation detection
Germ-line mutations in HR panel, which included 28 genes namely ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53, were detected using blood samples of 132 patients by targeted next-generation sequencing (NGS). Detailed procedure of targeted NGS was provided in the supplementary material, available at Annals of Oncology online. Patients with at least one pathogenic or likely-pathogenic mutation in any of the 28 genes were classified as HRD. Patients with at least one pathogenic or likely-pathogenic mutation in BRCA1 or BRCA2 were defined as gBRCA1/2-mutated.
PD-L1 expression, core-basal markers of EGFR and CK5/6 expression were assessed by immunohistochemistry in 114 samples following procedure reported previously, detail of which was provided in the supplementary material, available at Annals of Oncology online [8, 9] . PD-L1 was scored as reported in recent trials, where membranous staining of tumor and tumor-infiltrating immune cells were attributed separate scores on a 4-point scale as follows: 0, 1% positive cells; 1, 1%-5% positive cells; 2, 5%-10% positive cells; and 3, 10% positive cells [8, 10] . PD-L1 positivity was defined as at least 1% of positive tumor or tumorinfiltrating immune cells.
Assessment of tumor-infiltrating lymphocytes (TILs) were carried out on hematoxylin and eosin-stained sections using tissue samples from 114 patients. Lymphocyte-predominant BC (LPBC) was defined as BC with 50% of stromal or intratumoral TILs according to previous studies [11, 12] . Detailed procedures were provided in the supplementary material, available at Annals of Oncology online.
End point and statistical analysis
Primary interests were updated PFS and absolute 6-month PFS benefits between GP and GT arms. Wald test in Cox proportional hazards model was used to determine the significance of interaction. PFS and overall survival (OS) were generated by Kaplan-Meier method and assessed with Log-rank test. Relations between biomarkers and objective response rate (ORR) or 1-year PFS rate were analyzed with Pearson's v 2 test. Absolute 6-month PFS benefits between GP and GT arms were analyzed by nonparametric sliding-window subpopulation treatment effect pattern plot (STEPP) analysis following procedure in a previous report [13] . Briefly, seven parameters (age, disease-free interval, number of metastatic organs, visceral metastasis, previous chemotherapy of anthracycline, previous chemotherapy of taxane and gBRCA1/2 mutation) were chosen considering the results of biomarker analysis and on the basis of our previous research to construct a Cox proportional hazards model defining the composite measure of progression risk (referred to as composite risk). Then, the value of composite risk of each patient was calculated by summing the model parameter estimates according to her observed prognostic factor values. Nonparametric sliding-window STEPP analysis was used to investigate the patterns of absolute treatment effect between GP and GT arms, as measured by Kaplan-Meier estimates of 6-month PFS (y-axis) across the continuum of values of composite risk (x-axis). SPSS (version 19.0) and R (version 3.4.1) were used for statistical analysis. All statistical tests were two-tailed, with the significant level being set at P < 0.05.
Results
Updated survival analysis of CBCSG006 trial showed consistently significant improvement in PFS for GP arm compared with GT arm
The updated cutoff date for survival analysis was 27 May 2017, with a total of 212 patients having end point event. The median follow-up periods were 54.73 (IQR 47.50-60.77) months. Median PFS was 7.73 [95% confidence interval (CI) 6.46-9.00] months for GP arm and 6.07 (95% CI 5.32-6.83) months for GT arm ( Figure 1A , P ¼ 0.005), suggesting consistently superior efficacy for GP regimen compared with GT regimen. There were no significant differences in median OS between two arms ( Figure 1B) .
Predictors of cisplatin-based treatment performance
Overall results. In the overall population, there were no significant correlations between germ-line HR status, gBRCA1 There was significant interaction between HR status and treatment for PFS (interaction P ¼ 0.004). Patients classified as HRD had significantly higher ORR and longer PFS in GP arm than in GT arm (71.9% versus 38.7%, P ¼ 0.008; 10.37 versus 4.30 months, P ¼ 0.011), while there was no evidence of different efficacy in non-HRD patients (Figure 2A ). For OS, there was no significant interaction between HR status and treatment and no significant difference between two arms regardless HR status (supplementary Table S2 , available at Annals of Oncology online).
There were no significant interaction between gBRCA1/2 status and treatment for PFS (interaction P ¼ 0.485) and OS (supplementary Table S2 , available at Annals of Oncology online). Patients with gBRCA1/2 mutation had numerically higher ORR and prolonged PFS in GP arm than in GT arm (83.3% versus 37.5%, P ¼ 0.086; 8.90 versus 3.20 months, P ¼ 0.459), while there was no evidence of different efficacy in patients with wildtype BRCA1/2 ( Figure 2B) .
To investigate the predictive role of HR genes other than BRCA1/2 to platinum sensitivity, we generated a new HRD classification excluding BRCA1/2, referred to as HRD-without-BRCA1/2, and found it has significant interaction with treatment for PFS (interaction P ¼ 0.009) but not OS (supplementary Table S2 , available at Annals of Oncology online). HRD-without-BRCA1/2 classification significantly correlated with higher ORR and longer PFS in GP arm than in GT arm, but not OS (supplementary Figure  S2A and Table S2 , available at Annals of Oncology online).
PD-L1 expression: PD-L1 expression was assessed in 48.3% (114/236) patients, of whom 104 tissue sections were qualified for analysis. Baseline characteristics showed no significant difference compared with whole cohort (Table 1) . There was no significant interaction between PD-L1 status and treatment for PFS (interaction P ¼ 0.205) and OS (supplementary Table S2 , available at Annals of Oncology online), and no differences in ORR, PFS or OS between two arms regardless of PD-L1 status (Figure 2C and  supplementary Table S2 , available at Annals of Oncology online). However, in patients with positive PD-L1 status, 1-year PFS rate exhibited a directional improvement (GP versus GT: 36.4% versus 12.5%, P ¼ 0.243).
Other biomarkers: Core-basal subtype and TILs were assessed in 48.3% (114/236) patients. There were no significant interactions between core-basal subtypes or TIL status and treatment for PFS and OS, and no significant differences in ORR, PFS or OS in two arms regardless of core-basal subtype and TILs status (supplementary Figure S2B and C and Table S2 , available at Annals of Oncology online). Absolute survival benefits of GP treatment than GT treatment in patients with different composite risks: STEPP analysis About 132 patients were included in STEPP analysis. Result of the Cox proportional hazards model for defining the composite risk is presented in Table 2 . Distribution of composite risk scores are shown in Figure 3A . Overall, 6-month PFS rate was 54.8%, ranging from 70.7% to 25.6% among patients with composite risks from the lowest to highest quartiles ( Figure 3B ). STEPP analysis showed that the absolute benefit of 6-month PFS rate between GP and GT arm was highest in subgroup with lowest composite risk (nearly 40%), and became smaller with higher composite risks ( Figure 3C ). In the subgroup with highest composite risk, there was even slight negative impact on PFS of GP treatment ( Figure 3C ). No pattern in absolute benefits of 18-month OS rate was found, but basically GP arm had higher 18-month OS rates than GT arm ( Figure 3D ).
Discussion
The updated survival data of CBCSG006 trial showed that GP treatment prolonged first-line PFS by more than 1 month when compared with standard GT treatment. Recently, the tnAcity trial suggested that nab-paclitxel (ABX) plus carboplatin has superior efficacy than gemcitabine plus carboplatin regimen [14] . A clinical trial is underway to investigate whether ABX plus cisplatin has superior effect than GP (NCT02546934). No significant differences in OS were observed, mainly because of the confounding treatments subsequent to this trial, making the comparison of OS meaningless. Therefore, we mainly focused on the differences in PFS in biomarker analysis.
The possibly deleterious gBRCA1/2 mutation rate of TNBC we reported is consistent with previous wide screen studies in China [15, 16] . Although statistically insignificant, the absolute differences in ORR and PFS between patients with mutated and wildtype BRCA1/2 status were very obvious. Considering the low gBRCA1/2 mutation rate, a much larger cohort might be needed to ensure the detective power to its predictive value. In TNT trial, patients with gBRCA1/2 mutations had significantly higher ORR and longer PFS when treated with carboplatin than doxetaxel [5] . Taken together, two randomized trials have suggested the predictive value of gBRCA1/2 mutations in platinum treatment.
However, the role of HRD classification as a biomarker seems ambiguous. TNT and PrECOG0105 trial used Myriad assay to determine HR status. While PrECOG0105 trial found that HR status was significantly linked to higher response rate in carboplatin-combined therapy [3] , TNT trial found no evidence of treatment-specific benefits regardless of HR status [5] . Our study for the first time to our knowledge investigated an HR panel featuring germ-line mutations as a biomarker of cisplatin therapy. The significant relations we found between HR status and cisplatin doublet performance indicated the possibility of using HRD germ-line mutation panel as a biomarker. Even after we excluded gBRCA1/2 mutations from HR panel (HRD-without-BRCA1/2), it still significantly correlated with prolonger PFS, which indicated the predictive value of HR genes other than BRCA1/2 to platinum sensitivity. However, further validation in larger cohort is needed before any conclusion could be drawn. Given the lack of evidence of HR status as a biomarker and the Figure 2 . Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients with different status in germ-line HR genes (A), germ-line BRCA1/2 (B) and PD-L1 expression (C). HR, homologous recombination.
inconvenience of detection, in our following STEPP analysis, we included gBRCA1/2 status as a parameter. In our study, we found that PD-L1 positive patients tended to have higher 1-year PFS rate when treated with GP than GT regimen, contributing to a better long-term survival and indicating the possibility of combined therapy of PD-L1 inhibitor and platinum doublet. However, a larger clinical trial is needed to evaluate PD-L1 status as a biomarker for platinum performance.
By STEPP analysis, we found that patients with lower composite risk benefited more from GP regimen. We hypothesized that when tumors were more aggressive, they might respond worse or quickly develop resistance to chemotherapy regardless of what kind of drugs used, resulting in the insignificance in efficacy between different regimens.
Conclusion
In conclusion, we identified gBRCA1/2 mutations and HRD as possible biomarkers for better performance of platinum doublet and we recommend routine gBRCA1/2 detection. For the first time to our knowledge, a composite risk model was developed to guide selection of GP treatment in mTNBC patients but validations in larger clinical trials are needed. and tissue samples were collected or used after independent written informed consents were given by patients.
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